The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Are Vancomycin Trough Concentrations Adequate for Optimal Dosing?
Open accessAbstract
The current vancomycin therapeutic guidelines recommend the use of only trough concentrations to manage the dosing of adults with Staphylococcus aureus infections. Both vancomycin efficacy and toxicity are likely to be related to the area under the plasma concentration-time curve (AUC). We assembled richly sampled vancomycin pharmacokinetic data from three studies comprising 47 adults with various levels of renal function. With Pmetrics, the nonparametric population modeling package for R, we compared AUCs estimated from models derived from trough-only and peak-trough depleted versions of the full data set and characterized the relationship between the vancomycin trough concentration and AUC. The trough-only and peak-trough depleted data sets underestimated the true AUCs compared to the full model by a mean (95% confidence interval) of 23% (11 to 33%; P = 0.0001) and 14% (7 to 19%; P < 0.0001), respectively. In contrast, using the full model as a Bayesian prior with trough-only data allowed 97% (93 to 102%; P = 0.23) accurate AUC estimation. On the basis of 5,000 profiles simulated from the full model, among adults with normal renal function and a therapeutic AUC of ≥400 mg · h/liter for an organism for which the vancomycin MIC is 1 mg/liter, approximately 60% are expected to have a trough concentration below the suggested minimum target of 15 mg/liter for serious infections, which could result in needlessly increased doses and a risk of toxicity. Our data indicate that adjustment of vancomycin doses on the basis of trough concentrations without a Bayesian tool results in poor achievement of maximally safe and effective drug exposures in plasma and that many adults can have an adequate vancomycin AUC with a trough concentration of <15 mg/liter.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Moise-Broder, P. A., Forrest, A., Birmingham, M. C., & Schentag, J. J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443130-00005 · Cited by 757
Modeling and Simulation: Challenges and Best Practices for Industry
Dubois, G. (2018) · CRC Press eBooks · doi:10.1201/9781351241137 · Cited by 744
Wunderink, R. G., Niederman, M. S., Kollef, M. H., Shorr, A. F., Kunkel, M. J., Baruch, A., McGee, W. T., Reisman, A., & Chastre, J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir895 · Cited by 570
Lodise, T. P., Patel, N., Lomaestro, B. M., Rodvold, K. A., & Drusano, G. L. (2009) · Clinical Infectious Diseases · doi:10.1086/600884 · Cited by 554
Self-citationNeely, M. N., van Guilder, M. G., Yamada, W. M., Schumitzky, A., & Jelliffe, R. W. (2012) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31825c4ba6 · Cited by 470
Self-citationKullar, R., Davis, S. L., Levine, D. P., & Rybak, M. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir124 · Cited by 463 · cited 2×
“This probability of possibly toxic vancomycin exposure agrees well with four clinical studies that found early vancomycin trough concentrations of 20 mg/liter to be associated with subsequent nephrotoxicity in approximately 25 to 40% of patients (12, 13, 28, 29).”
BackgroundOptimal sampling times for pharmacokinetic experiments
D'Argenio, D. Z. (1981) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01070904 · Cited by 324
Improved Vancomycin Dosing in Children Using Area Under the Curve Exposure
Le, J., Bradley, J. S., Murray, W., Romanowski, G. L., Tran, T. T., Nguyen, N., Cho, S., Natale, S., Bui, I., Tran, T. M., et al. (2013) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318286378e · Cited by 262
Vancomycin pharmacokinetics in patients with various degrees of renal function
Rodvold, K. A., Blum, R. A., Fischer, J. H., Zokufa, H. Z., Rotschafer, J. C., Crossley, K. B., & Riff, L. J. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.6.848 · Cited by 249
Self-citationVancomycin: A Review of Population Pharmacokinetic Analyses
Marsot, A., Boulamery, A., Bruguerolle, B., & Simon, N. (2012) · Clinical Pharmacokinetics · doi:10.2165/11596390-000000000-00000 · Cited by 226
Vancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia
Holmes, N. E., Turnidge, J. D., Munckhof, W. J., Robinson, J. O., Korman, T. M., O'Sullivan, M. V. N., Anderson, T. L., Roberts, S. A., Warren, S. J. C., Gao, W., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01485-12 · Cited by 224
Cataldo, M. A., Tacconelli, E., Grilli, E., Pea, F., & Petrosillo, N. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr442 · Cited by 204
Cano, E. L., Haque, N. Z., Welch, V. L., Cely, C. M., Peyrani, P., Scerpella, E. G., Ford, K. D., Zervos, M. J., Ramirez, J. A., & Kett, D. H. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.12.013 · Cited by 161
Increasing Vancomycin Serum Trough Concentrations and Incidence of Nephrotoxicity
Pritchard, L., Baker, C., Leggett, J., Sehdev, P., Brown, A., & Bayley, K. B. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.07.025 · Cited by 161
Jelliffe, R. W. (2002) · American Journal of Nephrology · doi:10.1159/000065221 · Cited by 144
Self-citationAn adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) population models
Leary, R. H., Jelliffe, R. W., Schumitzky, A., & Guilder, M. V. (2002) · Proceedings - IEEE Symposium on Computer-Based Medical Systems · doi:10.1109/cbms.2001.941750 · Cited by 124
Self-citationBrown, J. E., Brown, K., & Forrest, A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05609-11 · Cited by 116
Suzuki, Y., Kawasaki, K., Sato, Y., Tokimatsu, I., Itoh, H., Hiramatsu, K., Takeyama, M., & Kadota, J. (2012) · Chemotherapy · doi:10.1159/000343162 · Cited by 110
Kullar, R., Davis, S. L., Taylor, T. N., Kaye, K. S., & Rybak, M. J. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2011.01017.x · Cited by 86
Gawronski, K. M., Goff, D. A., Brown, J. E., Khadem, T. M., & Bauer, K. A. A. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.05.008 · Cited by 74
Jelliffe, R. W., Bayard, D. S., Milman, M. H., Guilder, M. V., & Schumitzky, A. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200006000-00018 · Cited by 70
Self-citationVancomycin therapeutics and monitoring: a contemporary approach
Avent, M. L., Vaska, V. L., Rogers, B. A., Cheng, A. C., van Hal, S. J., Holmes, N. E., Howden, B. P., & Paterson, D. L. (2012) · Internal Medicine Journal · doi:10.1111/imj.12036 · Cited by 68
Tobin, C. M. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf212 · Cited by 67
A Bayesian Approach to Tracking Patients Having Changing Pharmacokinetic Parameters
Bayard, D. S., & Jelliffe, R. W. (2004) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/b:jopa.0000029490.76908.0c · Cited by 64
Self-citationPenetration of Vancomycin into Epithelial Lining Fluid in Healthy Volunteers
Lodise, T. P., Drusano, G. L., Butterfield, J. M., Scoville, J., Gotfried, M., & Rodvold, K. A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00712-11 · Cited by 60
Self-citationNunn, M. O., Corallo, C., Aubron, C., Poole, S. G., Dooley, M. J., & Cheng, A. C. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p634 · Cited by 60
Neely, M. N., & Jelliffe, R. W. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008321789 · Cited by 57
Self-citationMinne, L., Eslami, S., Kuiper, R., Abu–Hanna, A., & Dongelmans, D. A. (2012) · PubMed · Cited by 10
Cited by
Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research
Turner, N. A., Sharma-Kuinkel, B. K., Maskarinec, S. A., Eichenberger, E. M., Shah, P. P., Carugati, M., Holland, T. L., & Fowler, V. G. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0147-4 · Cited by 2,051
Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Wong-Beringer, A., Rotschafer, J. C., et al. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa036 · Cited by 1,202
Self-citationAntimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
Self-citationThe Nephrotoxicity of Vancomycin
Filippone, E., Kraft, W., & Farber, J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.726 · Cited by 416
Neely, M. N., Kato, L., Youn, G., Kraler, L., Bayard, D., van Guilder, M., Schumitzky, A., Yamada, W., Jones, B., & Minejima, E. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02042-17 · Cited by 359
Self-citation
Metadata
- Authors
- Neely, M. N., Youn, G., Jones, B., Jelliffe, R. W., Drusano, G. L., Rodvold, K. A., & Lodise, T. P.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2014-01
- Volume
- 58
- Issue
- 1
- Pages
- 309-316
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2010066166
- Cited by
- 392
- References
- 30
- FWCI
- 12.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.